Quest PharmaTech Inc. (QPTFF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Quest PharmaTech Inc. (QPTFF) trades at $0.02. Quest PharmaTech Inc. is a pharmaceutical company focused on developing antibody-based immunotherapeutic products for cancer treatment. Their lead product candidate, Mab AR 9. Market cap: $3.38M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for QPTFF: QPTFF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates QPTFF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
Not enough scored data yet to form a council read on QPTFF.
How is this calculated? →Quest PharmaTech Inc. (QPTFF) Healthcare & Pipeline Overview
Quest PharmaTech Inc., a Canadian biotechnology company, specializes in developing immunotherapeutic products, primarily focused on antibody-based cancer therapies. Their lead candidate, Mab AR 9.6, and other assets like Oregovomab, target specific cancer markers. The company also explores transdermal delivery technologies for dermatology and wound healing applications.
What Is the Investment Thesis for QPTFF?
Quest PharmaTech Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's lead product candidate, Mab AR 9.6, holds promise as a targeted cancer therapy, but its clinical development is still in early stages. Successful completion of clinical trials and regulatory approval are critical value drivers. The company's market capitalization of $3.38M reflects its early-stage nature and the inherent uncertainties associated with drug development. A potential catalyst is the advancement of Mab AR 9.6 through clinical trials, with positive data readouts potentially driving significant stock appreciation. The negative P/E ratio of -8.65 indicates that the company is currently not profitable, highlighting the reliance on future product commercialization for revenue generation. Key risks include clinical trial failures, regulatory hurdles, and the need for additional financing to support ongoing research and development activities.
Based on FMP financials and quantitative analysis
QPTFF Key Highlights
Lead product candidate Mab AR 9.6 targets truncated O-glycan on MUC16 for cancer therapy.
- Oregovomab, an anti-CA-125 antibody, has completed Phase II clinical trial for ovarian cancer treatment.
- Developing immunotherapy products for pancreatic cancer.
- Exploring proprietary transdermal delivery technologies for dermatology and wound healing.
- Market capitalization of $3.38M reflects its early-stage nature and the inherent uncertainties associated with drug development.
Who Are QPTFF's Competitors?
QPTFF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CLCS Cell Source, Inc. | $0.65 | +0.00% | $44.0M | 45 |
| HMTXF Hemostemix Inc. | $0.05 | +10.48% | $10.8M | 42 |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are QPTFF's Key Strengths?
Proprietary antibody-based immunotherapeutic technologies.
- Expertise in targeted cancer therapy development.
- Proprietary transdermal delivery technologies.
- Lead product candidate Mab AR 9.6 shows promise.
What Are QPTFF's Weaknesses?
Early-stage development company with limited revenue.
- Reliance on successful clinical trials and regulatory approvals.
- High cash burn rate and need for additional financing.
- Limited commercialization experience.
What Could Drive QPTFF Stock Higher?
Clinical trial results for Mab AR 9.6.
- Potential partnerships or collaborations with pharmaceutical companies.
- Development of new immunotherapy products for pancreatic cancer.
What Are the Key Risks for QPTFF?
Financial-distress signal — its Altman Z-Score of 1.27 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures.
- Regulatory hurdles and delays.
- Competition from established pharmaceutical companies.
- High cash burn rate and need for additional financing.
- Intellectual property challenges.
What Are the Growth Opportunities for QPTFF?
- Advancement of Mab AR 9.6: The successful advancement of Mab AR 9.6 through clinical trials represents a significant growth opportunity for Quest PharmaTech. Positive clinical data could lead to regulatory approval and commercialization, potentially generating substantial revenue. The timeline for commercialization depends on the successful completion of clinical trials, with potential launch within 5-7 years, pending regulatory approvals.
- Expansion of Immunotherapy Pipeline: Quest PharmaTech has the opportunity to expand its immunotherapy pipeline beyond Mab AR 9.6 and Oregovomab. Developing new antibody-based therapies targeting different cancer markers could broaden the company's addressable market and reduce its reliance on a single product. The global immunotherapy market is experiencing rapid growth, driven by the success of checkpoint inhibitors and other immunotherapeutic approaches. The timeline for developing new immunotherapy products typically involves several years of preclinical research and clinical trials.
- Development of Transdermal Delivery Technologies: Quest PharmaTech's proprietary transdermal delivery technologies offer a growth opportunity in the dermatology and wound healing markets. Developing skin-penetrating active molecules for cosmetic and pharmaceutical applications could generate revenue streams outside of cancer therapeutics. The transdermal drug delivery market is projected to grow significantly, driven by the increasing demand for non-invasive drug delivery methods. The timeline for commercializing transdermal products is typically shorter than that for cancer therapeutics, with potential launch within 2-3 years.
- Strategic Partnerships and Collaborations: Quest PharmaTech can pursue strategic partnerships and collaborations with larger pharmaceutical companies to accelerate the development and commercialization of its products. Partnering with established players can provide access to funding, expertise, and distribution networks. The pharmaceutical industry is increasingly relying on collaborations to drive innovation and expand product portfolios. The timeline for establishing partnerships can vary depending on the specific opportunity and the interests of potential partners.
- Expansion into New Geographic Markets: Quest PharmaTech can explore opportunities to expand its geographic reach beyond its current focus. Entering new markets, such as Europe and Asia, could increase the company's potential customer base and revenue streams. The global pharmaceutical market is highly fragmented, with significant growth opportunities in emerging markets. The timeline for entering new geographic markets depends on regulatory approvals and the establishment of distribution networks.
What Are QPTFF's Competitive Advantages?
- Proprietary antibody-based immunotherapeutic technologies.
- Expertise in targeted cancer therapy development.
- Proprietary transdermal delivery technologies.
- Intellectual property protection through patents and trade secrets.
What Does QPTFF Do?
Quest PharmaTech Inc., headquartered in Edmonton, Canada, is a pharmaceutical company dedicated to the development of innovative antibody-based immunotherapeutic products for the treatment of cancer. The company's origins lie in the pursuit of targeted cancer therapies, leveraging its expertise in antibody engineering and drug delivery systems. Quest PharmaTech's lead product candidate is Mab AR 9.6, a monoclonal antibody targeting truncated O-glycan on MUC16, a marker highly expressed in various cancers. This targeted approach aims to deliver therapeutic payloads directly to cancer cells, minimizing off-target effects. In addition to Mab AR 9.6, Quest PharmaTech's portfolio includes Oregovomab, an anti-CA-125 antibody that has completed Phase II clinical trials for the treatment of ovarian cancer. The company is also involved in developing immunotherapy products for pancreatic cancer. Beyond its core focus on cancer therapeutics, Quest PharmaTech is exploring the application of its proprietary transdermal delivery technologies in dermatology and wound healing. This includes the development of skin-penetrating active molecules for cosmetic and pharmaceutical applications. The company also investigates combinatorial immunotherapeutic products that combine monoclonal antibodies of the immunoglobulin G and E classes for enhanced cancer treatment efficacy. Quest PharmaTech operates in the highly competitive biotechnology landscape, striving to advance its pipeline of innovative therapies and improve outcomes for cancer patients.
What Products and Services Does QPTFF Offer?
- Develop antibody-based immunotherapeutic products for cancer treatment.
- Focus on targeted cancer therapy applications.
- Offer Oregovomab, an anti-CA-125 antibody, for ovarian cancer treatment.
- Develop immunotherapy products for pancreatic cancer.
- Utilize transdermal delivery technologies for dermatology and wound healing.
- Create skin-penetrating active molecules for cosmetic and pharmaceutical use.
- Develop combinatorial immunotherapeutic products for cancer treatment.
How Does QPTFF Make Money?
- Develop and license antibody-based immunotherapeutic technologies.
- Conduct research and development to create new cancer therapies.
- Out-license or partner for commercialization of developed products.
- Generate revenue through licensing fees, milestone payments, and royalties.
What Industry Does QPTFF Operate In?
Quest PharmaTech Inc. operates within the biotechnology industry, a sector characterized by high innovation, intense competition, and significant regulatory oversight. The company focuses on the development of immunotherapeutic products for cancer, a market driven by the increasing prevalence of cancer and the growing demand for targeted therapies. The competitive landscape includes established pharmaceutical companies and emerging biotechnology firms, all vying for market share in the oncology space. Quest PharmaTech's success depends on its ability to develop and commercialize innovative therapies that address unmet medical needs and differentiate itself from competitors.
Who Are QPTFF's Key Customers?
- Pharmaceutical companies seeking to in-license novel cancer therapies.
- Biotechnology companies interested in partnering for drug development.
- Patients with cancer who may benefit from new treatment options.
- Dermatology and cosmetic companies interested in transdermal delivery technologies.
Key Financial Metrics
Return on equity for Quest PharmaTech Inc. stands at 21.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 17.1%, showing how much profit it generates from its asset base. QPTFF trades at a trailing price-to-earnings ratio of 1.52, below the Healthcare sector average of ~23x. Its free cash flow yield is 0.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.02 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 65.7%, the inverse of the P/E and a quick read on earnings relative to price.
Quest PharmaTech Inc. (QPTFF) Valuation Context
Valued at $3.38M, QPTFF is classified as a micro-cap stock.
Company Profile
Quest PharmaTech Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Edmonton, CA. The company is led by CEO Ragupathy Madiyalakan. QPTFF has traded publicly since 2018.
Financial Health
Quest PharmaTech Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 1.27 places it in the distress zone, a signal of elevated financial risk.
QPTFF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Proprietary antibody-based immunotherapeutic technologies.
- Expertise in targeted cancer therapy development.
- Proprietary transdermal delivery technologies.
- Lead product candidate Mab AR 9.6 shows promise.
Bear Case
- Early-stage development company with limited revenue.
- Reliance on successful clinical trials and regulatory approvals.
- High cash burn rate and need for additional financing.
- Limited commercialization experience.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
QPTFF Latest News
No recent news available for QPTFF.
QPTFF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for QPTFF.
Price Targets
Wall Street price target analysis for QPTFF.
QPTFF MoonshotScore
What does this score mean?
The MoonshotScore rates QPTFF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Ragupathy Madiyalakan
CEO
Ragupathy Madiyalakan serves as the CEO of Quest PharmaTech Inc. His background includes extensive experience in the pharmaceutical and biotechnology industries, with a focus on drug development and commercialization. He has held leadership positions in various companies, overseeing research and development activities, clinical trials, and regulatory affairs. Madiyalakan's expertise spans multiple therapeutic areas, including oncology and dermatology. He is committed to advancing Quest PharmaTech's pipeline of innovative therapies and improving outcomes for patients.
Track Record: Under Ragupathy Madiyalakan's leadership, Quest PharmaTech has focused on advancing its lead product candidate, Mab AR 9.6, through preclinical and clinical development. He has also overseen the expansion of the company's immunotherapy pipeline and the exploration of transdermal delivery technologies. Key milestones include the completion of Phase II clinical trials for Oregovomab and the establishment of strategic partnerships to support research and development activities.
QPTFF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Quest PharmaTech Inc. may not meet the minimum financial or reporting requirements for higher tiers like OTCQB or OTCQX. Companies in this tier may have limited financial disclosures and may not be subject to the same level of regulatory scrutiny as companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries significant risks due to the potential for limited information and liquidity.
- OTC Tier: OTC Other
- Limited financial disclosure increases information asymmetry.
- Lower trading volume can lead to price volatility.
- Potential for delisting or trading suspensions.
- Higher risk of fraud or manipulation compared to listed exchanges.
- OTC Other tier companies may have difficulty raising capital.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and patent portfolio.
- Check for any legal or regulatory issues.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Development of antibody-based immunotherapeutic products for cancer treatment.
- Focus on targeted cancer therapy applications.
- Lead product candidate Mab AR 9.6 shows promise.
Quest PharmaTech Inc. Healthcare Stock: Key Questions Answered
What does Quest PharmaTech Inc. do?
Quest PharmaTech Inc. is a pharmaceutical company focused on developing antibody-based immunotherapeutic products for the treatment of cancer. Their primary focus is on targeted cancer therapies, with their lead product candidate, Mab AR 9.6, targeting truncated O-glycan on MUC16. They also offer Oregovomab, an anti-CA-125 antibody, which has completed Phase II clinical trials for ovarian cancer treatment.
What do analysts say about QPTFF stock?
As of 2026-03-16, there is no readily available analyst consensus on QPTFF stock, likely due to its OTC listing and small market capitalization. The company's valuation is heavily dependent on the successful development and commercialization of its pipeline products, particularly Mab AR 9.6. Investors should carefully consider the risks and uncertainties associated with drug development before investing in QPTFF.
What are the main risks for QPTFF?
The main risks for Quest PharmaTech Inc. include the inherent uncertainties associated with drug development, such as clinical trial failures and regulatory hurdles. The company's financial position is also a risk, as it is currently not profitable and relies on additional financing to support its research and development activities.
What are the key factors to evaluate for QPTFF?
Evaluate QPTFF on fundamentals, analyst consensus, and risk factors. Quest PharmaTech Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. Not financial advice.
How frequently does QPTFF data refresh on this page?
QPTFF's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven QPTFF's recent stock price performance?
Quest PharmaTech Inc. (QPTFF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary antibody-based immunotherapeutic technologies. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider QPTFF overvalued or undervalued right now?
Quest PharmaTech Inc. (QPTFF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research QPTFF before investing?
Before investing in Quest PharmaTech Inc. (QPTFF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on OTC-listed companies.
- Financial data may not be readily available or up-to-date.